The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells

Nicole Baptiste, Philip Friedlander, Xinbin Chen, Carol Prives

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

In some cell types either DNA damage or p53 expression leads to minimal cell death, while combining the two leads to a strong apoptotic response. To further understand features of p53 that contribute to this increased cell death we used clones of H1299 cells that express wild-type or several mutant forms of p53 under a tetracycline-regulated promoter. In these cells the induction of wild-type p53 leads to significant apoptosis only when combined with exposure to a number of chemotherapeutic agents. A common target of p53, p21, is itself not sufficient to cause apoptosis in the presence of these chemotherapeutic compounds. Many agents also effectively increase cell death when a transcriptionally-defective p53, p53[gln22ser23], is induced, although a dramatic exception is treatment with 5-FU, which strongly cooperates with wild-type but not p53[gln22ser23]. Our results with 5-FU thus show that genetically separable functions of p53 are involved in its ability to respond to DNA-damaging agents to induce apoptosis. Notably as well, deleting the C-terminal 30 amino acids of p53 does not affect this cooperative effect with DNA-damaging agents. By contrast, a p53 mutant lacking the PXXP-domain between residues 60-90, while at least partially transcriptionally-competent, cannot be rendered apoptotic by any compounds that we tested. Thus the PXXP domain provides an essential component of the ability of p53 to respond to DNA-damaging agents to cause cell death.

Original languageEnglish (US)
Pages (from-to)9-21
Number of pages13
JournalOncogene
Volume21
Issue number1
DOIs
StatePublished - Jan 3 2002
Externally publishedYes

Fingerprint

Proline
Cell Death
Apoptosis
Fluorouracil
DNA
Neoplasms
Tetracycline
DNA Damage
Cause of Death
Clone Cells
Amino Acids

Keywords

  • Anti-neoplastics
  • Apoptosis
  • p53
  • Proline-rich domain

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. / Baptiste, Nicole; Friedlander, Philip; Chen, Xinbin; Prives, Carol.

In: Oncogene, Vol. 21, No. 1, 03.01.2002, p. 9-21.

Research output: Contribution to journalArticle

Baptiste, Nicole ; Friedlander, Philip ; Chen, Xinbin ; Prives, Carol. / The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. In: Oncogene. 2002 ; Vol. 21, No. 1. pp. 9-21.
@article{e9ca3b6e6ff04f9c859d7f148b62a2bb,
title = "The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells",
abstract = "In some cell types either DNA damage or p53 expression leads to minimal cell death, while combining the two leads to a strong apoptotic response. To further understand features of p53 that contribute to this increased cell death we used clones of H1299 cells that express wild-type or several mutant forms of p53 under a tetracycline-regulated promoter. In these cells the induction of wild-type p53 leads to significant apoptosis only when combined with exposure to a number of chemotherapeutic agents. A common target of p53, p21, is itself not sufficient to cause apoptosis in the presence of these chemotherapeutic compounds. Many agents also effectively increase cell death when a transcriptionally-defective p53, p53[gln22ser23], is induced, although a dramatic exception is treatment with 5-FU, which strongly cooperates with wild-type but not p53[gln22ser23]. Our results with 5-FU thus show that genetically separable functions of p53 are involved in its ability to respond to DNA-damaging agents to induce apoptosis. Notably as well, deleting the C-terminal 30 amino acids of p53 does not affect this cooperative effect with DNA-damaging agents. By contrast, a p53 mutant lacking the PXXP-domain between residues 60-90, while at least partially transcriptionally-competent, cannot be rendered apoptotic by any compounds that we tested. Thus the PXXP domain provides an essential component of the ability of p53 to respond to DNA-damaging agents to cause cell death.",
keywords = "Anti-neoplastics, Apoptosis, p53, Proline-rich domain",
author = "Nicole Baptiste and Philip Friedlander and Xinbin Chen and Carol Prives",
year = "2002",
month = "1",
day = "3",
doi = "10.1038/sj.onc.1205015",
language = "English (US)",
volume = "21",
pages = "9--21",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells

AU - Baptiste, Nicole

AU - Friedlander, Philip

AU - Chen, Xinbin

AU - Prives, Carol

PY - 2002/1/3

Y1 - 2002/1/3

N2 - In some cell types either DNA damage or p53 expression leads to minimal cell death, while combining the two leads to a strong apoptotic response. To further understand features of p53 that contribute to this increased cell death we used clones of H1299 cells that express wild-type or several mutant forms of p53 under a tetracycline-regulated promoter. In these cells the induction of wild-type p53 leads to significant apoptosis only when combined with exposure to a number of chemotherapeutic agents. A common target of p53, p21, is itself not sufficient to cause apoptosis in the presence of these chemotherapeutic compounds. Many agents also effectively increase cell death when a transcriptionally-defective p53, p53[gln22ser23], is induced, although a dramatic exception is treatment with 5-FU, which strongly cooperates with wild-type but not p53[gln22ser23]. Our results with 5-FU thus show that genetically separable functions of p53 are involved in its ability to respond to DNA-damaging agents to induce apoptosis. Notably as well, deleting the C-terminal 30 amino acids of p53 does not affect this cooperative effect with DNA-damaging agents. By contrast, a p53 mutant lacking the PXXP-domain between residues 60-90, while at least partially transcriptionally-competent, cannot be rendered apoptotic by any compounds that we tested. Thus the PXXP domain provides an essential component of the ability of p53 to respond to DNA-damaging agents to cause cell death.

AB - In some cell types either DNA damage or p53 expression leads to minimal cell death, while combining the two leads to a strong apoptotic response. To further understand features of p53 that contribute to this increased cell death we used clones of H1299 cells that express wild-type or several mutant forms of p53 under a tetracycline-regulated promoter. In these cells the induction of wild-type p53 leads to significant apoptosis only when combined with exposure to a number of chemotherapeutic agents. A common target of p53, p21, is itself not sufficient to cause apoptosis in the presence of these chemotherapeutic compounds. Many agents also effectively increase cell death when a transcriptionally-defective p53, p53[gln22ser23], is induced, although a dramatic exception is treatment with 5-FU, which strongly cooperates with wild-type but not p53[gln22ser23]. Our results with 5-FU thus show that genetically separable functions of p53 are involved in its ability to respond to DNA-damaging agents to induce apoptosis. Notably as well, deleting the C-terminal 30 amino acids of p53 does not affect this cooperative effect with DNA-damaging agents. By contrast, a p53 mutant lacking the PXXP-domain between residues 60-90, while at least partially transcriptionally-competent, cannot be rendered apoptotic by any compounds that we tested. Thus the PXXP domain provides an essential component of the ability of p53 to respond to DNA-damaging agents to cause cell death.

KW - Anti-neoplastics

KW - Apoptosis

KW - p53

KW - Proline-rich domain

UR - http://www.scopus.com/inward/record.url?scp=0037012041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037012041&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1205015

DO - 10.1038/sj.onc.1205015

M3 - Article

C2 - 11791172

AN - SCOPUS:0037012041

VL - 21

SP - 9

EP - 21

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 1

ER -